Special Issue

Lymphomas: From Mechanisms to Therapeutic Approaches

Message from the Guest Editors

We are facing a revolution in lymphoma research, with novel approaches ranging from targeted therapies to cellular therapies like CAR T-cell therapy. The outcomes of patients are better in terms of prolonged overall survival and progression-free survival while maintaining an adequate quality of life. This would not be possible without in vitro and in vivo research models of lymphomas and phase I/II clinical trials pioneering a personalized medicine approach within hematology. where one size does not fit all. We are witnessing how the extreme efforts of experts of a multidisciplinary community, ranging from basic medicine to fruitful phase III randomized clinical trials, at every stage of lymphoma treatment can make a difference. As lymphomas are orphan diseases, breakthrough developments in novel drugs by regulatory agencies are the ultimate goal. I invite you to submit preclinical or early clinical data to try to make a difference, not only to the wealth of research but for individuals living with lymphoma.

Guest Editors

Dr. Delfa Radić-Krišto

School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

Dr. Vibor Milunović

Division of Hematology, Clinical Hospital Merkur, 10000 Zagreb, Croatia

Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/232596

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).